Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dengue tetravalent vaccine - Takeda

Next Previous
Drug Profile

Dengue tetravalent vaccine - Takeda

Alternative Names: DEN1-DEN2-DEN3-DEN4 vaccine - Takeda; Dengue tetravalent vaccine (live, attenuated) - Takeda; Dengue vaccine tetravalent - Takeda; DENVax™; Needle-free dengue vaccine; QDENGA; Qdenga; TAK-003; TDV - Takeda; Tetravalent dengue vaccine - Takeda

Latest Information Update: 13 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centers for Disease Control and Prevention; Inviragen
  • Developer PharmaJet; Takeda
  • Class Attenuated vaccines; Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dengue

Most Recent Events

  • 31 Jan 2025 Phase-II/III clinical trials in Dengue (Prevention, In adolescents, In children, In adults) in Japan (SC) (NCT06741683)
  • 19 Dec 2024 Takeda plans a phase-II/III trial for Dengue (Prevention, In children, In adolescents, In adults) in January 2025 (SC), (NCT06741683)
  • 04 Nov 2024 Takeda plans a phase III trial for Dengue (Prevention, In infants) in Colombia and Thailand (SC), in April 2025 (NCT06665035)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top